BACKGROUND: The cyclooxygenase-2 (COX-2) enzyme, which is induced by inflammatory and mitogenic stimuli, plays a protumorigenic role in several human cancers. COX-2 is overexpressed in invasive and in situ breast cancers. Atypical hyperplasia in breast tissue, although benign, is associated with a high risk of breast cancer. We investigated whether COX-2 overexpression in atypical hyperplasia is associated with the risk of subsequent breast cancer. METHODS: COX-2 expression was assessed immunohistochemically in archival sections from 235 women with atypia whose biopsy specimens were obtained at the Mayo Clinic from January 1, 1967, through December 31, 1991. COX-2 expression was scored as 0 (negative), 1+ (weak), 2+ (moderate), or 3+ (strong). Risk factor information and follow-up for breast cancer events were obtained via a study questionnaire and the medical records. All statistical tests were two-sided. RESULTS: Forty-one (17%) of the 235 women developed breast cancer during a median follow-up of 15 years. Moderate (category 2+) or strong (category 3+) COX-2 expression was identified in 71 (30%) and 34 (14%) of the 235 samples, respectively. The risk for developing breast cancer, relative to a control population (the Iowa Surveillance, Epidemiology, and End Results registry), increased with increasing COX-2 expression (relative risk [RR] = 2.63, 95% confidence interval [CI] = 1.56 to 4.15, for those with negative or weak COX-2 expression; RR = 3.56, 95% CI = 1.94 to 5.97, for those with moderate expression; and RR = 5.66, 95% CI = 2.59 to 10.75, for those with strong expression; P = .07). Overexpression of COX-2 was statistically significantly associated with the type of atypia (lobular vs ductal, P < .001), number of foci of atypia in the biopsy (P = .02), and older age at time of biopsy (>45 years, P = .01). CONCLUSIONS: COX-2 appears to be a biomarker that further stratifies breast cancer risk among women with atypia and may be a relevant target for chemoprevention strategies.
BACKGROUND: The cyclooxygenase-2 (COX-2) enzyme, which is induced by inflammatory and mitogenic stimuli, plays a protumorigenic role in several humancancers. COX-2 is overexpressed in invasive and in situ breast cancers. Atypical hyperplasia in breast tissue, although benign, is associated with a high risk of breast cancer. We investigated whether COX-2 overexpression in atypical hyperplasia is associated with the risk of subsequent breast cancer. METHODS:COX-2 expression was assessed immunohistochemically in archival sections from 235 women with atypia whose biopsy specimens were obtained at the Mayo Clinic from January 1, 1967, through December 31, 1991. COX-2 expression was scored as 0 (negative), 1+ (weak), 2+ (moderate), or 3+ (strong). Risk factor information and follow-up for breast cancer events were obtained via a study questionnaire and the medical records. All statistical tests were two-sided. RESULTS: Forty-one (17%) of the 235 women developed breast cancer during a median follow-up of 15 years. Moderate (category 2+) or strong (category 3+) COX-2 expression was identified in 71 (30%) and 34 (14%) of the 235 samples, respectively. The risk for developing breast cancer, relative to a control population (the Iowa Surveillance, Epidemiology, and End Results registry), increased with increasing COX-2 expression (relative risk [RR] = 2.63, 95% confidence interval [CI] = 1.56 to 4.15, for those with negative or weak COX-2 expression; RR = 3.56, 95% CI = 1.94 to 5.97, for those with moderate expression; and RR = 5.66, 95% CI = 2.59 to 10.75, for those with strong expression; P = .07). Overexpression of COX-2 was statistically significantly associated with the type of atypia (lobular vs ductal, P < .001), number of foci of atypia in the biopsy (P = .02), and older age at time of biopsy (>45 years, P = .01). CONCLUSIONS:COX-2 appears to be a biomarker that further stratifies breast cancer risk among women with atypia and may be a relevant target for chemoprevention strategies.
Authors: Amy C Degnim; Daniel W Visscher; Tanya L Hoskin; Marlene H Frost; Robert A Vierkant; Celine M Vachon; V Shane Pankratz; Derek C Radisky; Lynn C Hartmann Journal: Breast Cancer Res Treat Date: 2011-09-01 Impact factor: 4.872
Authors: Derek C Radisky; Marta Santisteban; Hal K Berman; Mona L Gauthier; Marlene H Frost; Carol A Reynolds; Robert A Vierkant; V Shane Pankratz; Daniel W Visscher; Thea D Tlsty; Lynn C Hartmann Journal: Cancer Prev Res (Phila) Date: 2011-09-15
Authors: Colleen Fordyce; Tim Fessenden; Curtis Pickering; Jason Jung; Veena Singla; Hal Berman; Thea Tlsty Journal: Cancer Prev Res (Phila) Date: 2009-12-22
Authors: Marta Santisteban; Carol Reynolds; Emily G Barr Fritcher; Marlene H Frost; Robert A Vierkant; Stephanie S Anderson; Amy C Degnim; Daniel W Visscher; V Shane Pankratz; Lynn C Hartmann Journal: Breast Cancer Res Treat Date: 2009-09-23 Impact factor: 4.872
Authors: V Shane Pankratz; Lynn C Hartmann; Amy C Degnim; Robert A Vierkant; Karthik Ghosh; Celine M Vachon; Marlene H Frost; Shaun D Maloney; Carol Reynolds; Judy C Boughey Journal: J Clin Oncol Date: 2008-10-14 Impact factor: 44.544
Authors: Min Hu; Guillermo Peluffo; Haiyan Chen; Rebecca Gelman; Stuart Schnitt; Kornelia Polyak Journal: Proc Natl Acad Sci U S A Date: 2009-02-13 Impact factor: 11.205
Authors: Lisa D Yee; Deepak Agarwal; Thomas J Rosol; Amy Lehman; Min Tian; Jennifer Hatton; Jessica Heestand; Martha A Belury; Steven K Clinton Journal: Mol Nutr Food Res Date: 2012-12-05 Impact factor: 5.914